Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock Read more about Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock
Aimmune Therapeutics Announces Proposed Public Offering of Common Stock Read more about Aimmune Therapeutics Announces Proposed Public Offering of Common Stock
Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy Read more about Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy
Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D. Read more about Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D.
Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress Read more about Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress
Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy Read more about Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy
Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy Read more about Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy
